Publications by authors named "D Dobreanu"
High long-term mortality in ischaemic heart disease accentuated among ethnic minorities in Eastern Europe: findings from a prospective all-comers percutaneous coronary intervention registry in Romania.
J Epidemiol Community Health
November 2024
Article Synopsis
- Long-term outcomes of cardiovascular diseases in Eastern Europe, specifically in a Romanian PCI registry, were assessed, focusing on ethnic minorities like Hungarians and Roma.
- The study analyzed data from 6,867 patients over a median follow-up of 3.60 years, revealing a total of 1,064 cardiovascular-related deaths and 1,374 all-cause deaths, with ethnic minorities experiencing higher mortality rates.
- Findings indicated significantly worse long-term survival rates for Hungarian and Roma patients compared to the Romanian population, highlighting disparities in health outcomes among these groups.
Aims: Compared to heart failure (HF) with reduced ejection fraction, HF with preserved ejection fraction (HFpEF), and HF with mildly reduced ejection fraction (HFmrEF) are increasing in prevalence, yet little is known about the geographic variation in patient characteristics, treatments and outcomes among these two HF phenotypes. The aim of this study was to investigate geographic differences in HFpEF and HFmrEF.
Methods And Results: We conducted an individual patient analysis of five clinical trials enrolling patients with HFpEF or HFmrEF from North America (NA), Latin America (LA), Western Europe (WE), Central/Eastern Europe and Russia (CEER), and Asia-Pacific (AP).
Article Synopsis
- Dapagliflozin is shown to enhance health outcomes in heart failure patients through improved scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) in a recent study (DELIVER trial).
- The analysis focused on how dapagliflozin treatment affected individual KCCQ items, providing insights for clinicians to communicate treatment impact.
- Results indicated significant improvements in various KCCQ components after 8 months of dapagliflozin treatment, especially regarding symptoms like lower limb edema and sleep issues related to shortness of breath.
Background: How patient characteristics and outcomes vary according to the duration of heart failure (HF) is unknown in individuals with mildly reduced or preserved ejection fraction. We compared these, and the efficacy and safety of dapagliflozin, according to the time from diagnosis of HF in a prespecified analysis of the DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure).
Methods: HF duration was categorized as ≤6 months, >6 to 12 months, >1 to 2 years, >2 to 5 years, or >5 years.
Aims: This pre-specified analysis of the DELIVER trial examined whether clinical benefits of dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF) >40% varied by baseline New York Heart Association (NYHA) class and examined the treatment effects on NYHA class over time.
Methods And Results: Treatment effects of dapagliflozin by baseline NYHA class II (n = 4713) versus III/IV (n = 1549) were examined on the primary endpoint (cardiovascular death or worsening HF event) and key secondary endpoints. Effects of dapagliflozin on change in NYHA class at 4, 16, and 32 weeks were also evaluated.